KORTUC
29.7.2021 14:02:14 CEST | Business Wire | Press release
Today KORTUC Inc. , a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.
KORTUC will use the financing to fund Research and Development activities, accelerate its Pivotal Phase II Study in the UK and pursue additional Pivotal Studies in the US. Currently ongoing Pivotal Phase II Study focuses on application of Kortuc radiosensitizer to locally advanced/recurrent breast cancer patients undergoing RT.
Comments from KORTUC
“We are pleased to share our vision with and receive such strong support from our new investor as we are accelerating our clinical research in the UK and the US to bring to cancer patients globally a product that can make a true difference in the near future – we firmly believe that Kortuc radiosensitizer can change the paradigm for use of radiotherapy across cancer types and stages” highlighted Kazu Matsuda, Chief Executive Officer of KORTUC.
Comments from AXA Japan
“As a worldwide leader in insurance and asset management, our purpose is to act for human progress by protecting what matters. As new cancer patient growth accelerates, this investment illustrates our purpose to support innovative technologies that can serve humanity.” Jean-Baptiste Tricot, Director, Executive Officer and Chief Financial Officer of AXA Japan commented.
Boris Moutier, Corporate Officer of AXA Japan, Japan and Asia Chief Investment Officer, also highlights that “With this brand new radiosensitizer, KORTUC has great potential to become a ground-breaking player in cancer treatment field, and we are glad to engage in this greatly promising journey. Aligned with AXA Group’s vision, AXA Japan pursues investments into startups that may create innovations and produce tangible results.”
About KORTUC Inc.
KORTUC Inc is a clinical-stage biopharmaceutical company headquartered in Tokyo, Japan. KORTUC’s Pivotal Phase II Study is currently ongoing in the UK with Royal Marsden Hospital and a number of cancer centers*1
across the UK focusing on locally advanced, recurrent breast cancer. Phase I study was completed in 2019 successfully demonstrating the product’s safety and efficacy, while related publication was accepted by Red Journal
(ASTRO) in June 2020.
About AXA Japan
AXA Japan is the Japanese arm of the AXA Group established in 1994. AXA Japan serves 2.64 million customers with 4.87 million policies by utilizing global expertise and experience of the AXA Group. Through partnerships with 511 Chambers of Commerce and Industry, private companies, and public offices across Japan, which have been built since the establishment of Nippon Dantai Life Insurance in 1934, AXA Japan offers a wide range of products, including death protection, medical/cancer protection, annuities, and asset accumulation, as well as advice on improving corporate welfare and Life Management®. In fiscal 2020, the company supported customers by paying 234.4 billion yen in claims and in annuity and maturity payouts.
About AXA Group
The AXA Group is a worldwide leader in insurance and asset management, with 153,000 employees serving 105 million clients in 54 countries. In 2020, IFRS revenues amounted to Euro 96.7 billion and underlying earnings to Euro 4.3 billion. AXA had Euro 1,032 billion in assets under management as of December 31, 2020. The AXA ordinary share is listed on compartment A of Euronext Paris under the ticker symbol CS (ISN FR 0000120628 – Bloomberg: CS FP – Reuters: AXAF.PA). AXA’s American Depository Share is also quoted on the OTC QX platform under the ticker symbol AXAHY. The AXA Group is included in the main international SRI indexes, such as Dow Jones Sustainability Index (DJSI) and FTSE4GOOD. It is a founding member of the UN Environment Programme’s Finance Initiative (UNEP FI) Principles for Sustainable Insurance and a signatory of the UN Principles for Responsible Investment.
*1 Clinical sites for Pivotal Phase II study
- The Royal Marsden NHS Foundation Trust, London, UK
- University Hospitals of North Midlands, Stoke-on-Trent, UK
- Beatson West of Scotland Cancer Centre, Glasgow, UK
- The Christie NHS Foundation Trust, Manchester, UK
- Royal Cornwall Hospital NHS Trust, Truro, UK
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005431/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Western Europe’s Fashion E-commerce Market Matures, Representing 20% of Online Consumer Spending as Gen Z Drives momentum30.7.2026 09:00:00 CEST | Press release
Second-hand platforms and value-focused retailers are disrupting Western Europe’s fashion market, which accounts for nearly one-fifth of online spending Fashion remains one of the largest and most resilient categories in Western European e-commerce, accounting for approximately 20% of online consumer spending across key markets, according to the latest NIQ (NYSE: NIQ) report, Decoding the Fashion E-commerce European Market in 2026. The study analyzes the behaviour of more than 2 million online shoppers across 10 European countries, providing one of the most comprehensive views of the region’s online fashion landscape. While fashion continues to play a central role in e-commerce, the category is entering a new phase of maturity. Across Europe, total e-commerce sales grew by 5% over the past year, compared with 3% growth for online fashion sales, highlighting the need for brands and retailers to find new avenues for growth. Key findings of the report: Fashion remains a core e-commerce ca
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track30.7.2026 08:37:00 CEST | Press release
Solid first quarter performance broadly in line with guidance, underpinned by resilient demand across core in-line brandsCommercial execution and late-stage pipeline investments on schedule, including first approval for ORZEYFULTM (oveporexton) in China, setting the foundation for next wave of medicinesNo change to FY2026 full-year forecast and management guidance Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined execution and operational momentum. Takeda leveraged the resilient performance of its core in-line portfolio to support its long-term strategy, advancing commercial launch preparations and driving critical R&D pipeline milestones. With a clear operational trajectory established in the first quarter and under a new operating model, Takeda remains on track to deliver its strategic and financial commitments for the fiscal year. FY2026 First Quarter Highlights Revenue
Coulson Aviation Introduces CFR HALO, a Long-Term Fire Retardant Engineered for Modern Aerial Firefighting30.7.2026 08:03:00 CEST | Press release
First Coulson EmberWorks product is undergoing qualification in France and evaluation for inclusion on the USDA Forest Service Qualified Products List Coulson Aviation today introduced CFR HALO, a next-generation long-term fire retardant engineered specifically for modern aircraft, tank systems, and wildfire missions. It is the first product from Coulson EmberWorks, the company’s research and development division dedicated to advancing aerial firefighting technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729960073/en/ Coulson Aviation has introduced CFR HALO, a next-generation long-term fire retardant engineered specifically for modern aircraft, tank systems and wildfire missions. It is designed with mission-optimized viscosity and flow characteristics to improve drop cohesion, reduce airborne drift, and support more accurate placement within the intended target area. CFR HALO is currently advancing through ind
SES Reports H1 2026 Results & Reiterates Full-Year Outlook30.7.2026 07:30:00 CEST | Press release
SES S.A. announces financial results for the three and six months ended June 30, 2026. H1 2026 Performance (€ million) H1 2026 as reported (1) H1 2025 as reported (1) ∆ At constant FX (2) H1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.17 1.08 1.08 Revenue 1,602 978 +72.4% 1,799 -5.0% Adjusted EBITDA (4) 725 521 +47.0% 824 -6.2% 1) ‘Reported basis’ with Intelsat fully consolidated from July 17, 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX rates to neutralize currency variations 3) ‘Like-for-like basis’ is as if Intelsat was fully consolidated from January 1, 2024 4) Excluding operating expenses/income recognized in relation to U.S. C-band repurposing, other income non-recurring, fair value movement on contingent value rights and other significant special items (disclosed separately) Networks revenue up +89.0% yoy(1) supported by growth in Mobility (+169.9% yoy(1); including positive impact from a contract restructuring in
AB InBev Reports Second Quarter 2026 Results30.7.2026 07:02:00 CEST | Press release
Solid top- and bottom-line performance: Revenue up by 5.6%, Beer volume growth of 1.1% and a 23.4% Underlying EPS increase Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729033132/en/ Regulated information1 “Cheers to beer – our performance this quarter reflects the strength of the beer category and the consistent execution of our strategy. Through investment in our megabrands and mega platforms, innovation and offering more choices across more occasions, we are strengthening the cultural relevance of our brands with consumers. Thank you to our colleagues for their commitment and disciplined execution, which position us well to continue our momentum.” – Michel Doukeris, CEO, AB InBev Revenue +5.6% Revenue increased by 5.6% in 2Q26 with revenue per hl growth of 4.2% and by 5.7% in HY26 with revenue per hl growth of 4.3%. Reported revenue increased by 11.0%
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom